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The objective of this study was to evaluate and understand the systematic error 
between the planned three-dimensional (3D) dose and the delivered dose to patient 
in scanning beam proton therapy for lung tumors. Single-field and multifield 
optimized scanning beam proton therapy plans were generated for ten patients 
with stage II-III lung cancer with a mix of tumor motion and size. 3D doses in CT 
datasets for different respiratory phases and the time-weighted average CT, as well 
as the four-dimensional (4D) doses were computed for both plans. The 3D and 4D 
dose differences for the targets and different organs at risk were compared using 
dose-volume histogram (DVH) and voxel-based techniques, and correlated with 
the extent of tumor motion. The gross tumor volume (GTV) dose was maintained 
in all 3D and 4D doses, using the internal GTV override technique. The DVH and 
voxel-based techniques are highly correlated. The mean dose error and the standard 
deviation of dose error for all target volumes were both less than 1.5% for all but 
one patient. However, the point dose difference between the 3D and 4D doses was 
up to 6% for the GTV and greater than 10% for the clinical and planning target 
volumes. Changes in the 4D and 3D doses were not correlated with tumor motion. 
The planning technique (single-field or multifield optimized) did not affect the 
observed systematic error. In conclusion, the dose error in 3D dose calculation varies 
from patient to patient and does not correlate with lung tumor motion. Therefore, 
patient-specific evaluation of the 4D dose is important for scanning beam proton 
therapy for lung tumors.
PACS number: 87.55.D




Scanning beam proton therapy may deliver a lower dose to normal tissue than does passive 
scatter proton therapy (PSPT) or intensity-modulated (photon) radiation therapy (IMRT).(1) In 
a previous investigation,(2) we developed an effective and practical method for proton therapy 
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planning for lung tumors using internal gross tumor volume (IGTV) override, a proper  smearing 
margin, and planning on time-averaged computed tomography (CT; average replacement of 
the internal gross tumor volume or AVE_RIGTV plan) for PSPT. However, a major concern 
in scanning beam proton therapy for lung cancer is the dose uncertainty caused by internal 
organ motion resulting from breathing, which may lead to a dose distribution that differs 
drastically from the planned distribution. This uncertainty might be larger than PSPT in scan-
ning beam proton therapy because of the lack of smearing margin.(3) Researchers have shown 
that this dose uncertainty consists of two components: 1) the systematic difference between 
the conventionally calculated dose using a three-dimensional (3D) CT dataset (3D dose) and 
the four-dimensional (4D) accumulated dose, which is the time-weighted average of the dose 
calculated in all respiratory phases (4D dose); and 2) a random component resulting from the 
difference between dynamically delivered and the stationary-calculated dose.(4-8) The system-
atic component is sometimes referred to as motion blurring (of the dose), whereas the random 
component is often referred to as the interplay effect; however, the definitions were previously 
ambiguous. Also, researchers showed that, whereas the random component can be controlled 
or even eliminated with the use of change delivery parameters such as repainting or elongating 
the treatment delivery time,(4,8,9) the systematic component can only be eliminated using the 
4D dose, which is an unbiased estimator of the delivered dose. Therefore, before applying the 
AVE_RIGTV planning technique to scanning beam proton therapy, investigating the systematic 
error emerging from the dose calculation performed using a 3D image set is necessary. In the 
study described herein, we examined the systematic error using the 3D dose, instead of the 
4D dose, for scanning beam proton therapy in the treatment planning stage with dose-volume 
histogram (DVH)- and voxel-based techniques, and investigated the relationship between the 
error and lung tumor motion. 
 
II. MAtErIALS AnD MEtHoDS
A.  Patients and plans
Ten patients with stage II-III lung cancer treated with IMRT or PSPT at UT MD Anderson 
Cancer Center from March 2010 to June 2012 were selected for this retrospective study. The 
patients were selected for a spread of tumor motion and volume. Each patient’s treatment 
parameters are listed in Table 1.
All patients underwent 4D CT simulation(10) using a T-bar handgrip, wing boards, and a 
vacuum immobilization device (Vac-Loc; CIVCO Medical Solutions, Kalona, IA) with GE 
LightSpeed 16 slice CT scanner (GE Healthcare, Waukesha, WI). Scans covering the entire 
lung volume, thorax, and upper abdomen were taken with a 2.5 mm slice spacing. The patients’ 
respiratory phases were determined using an infrared reflecting marker and camera system 
Table 1. Treatment parameters for the ten study patients with lung cancer.
  Center of GTV Motion GTV CTV
 Patient (mm) (cc) (cc) Number of Beams
 1 9 64.4 242.4 2
 2 9 70.7 196.3 3
 3 17 42.8 158.9 2
 4 7 80.4 299.8 3
 5 5 46.6 166.9 3
 6 8 165.5 539.6 2
 7 10 110.3 395.1 3
 8 8 73.1 203.3 3
 9 12 51.9 289.5 3
 10 8 46.6 191.6 3
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(Real-time Position Management System; Varian Medical Systems, Palo Alto, CA) and image 
bins corresponding to 10 equal phases, namely, T0–T90, with T0 defined as the full inhalation 
phase and T50 as the full exhalation phase. Each 4D CT dataset, therefore, consisted of ten 3D 
image sets corresponding to the 10 respiratory phases, with maximum intensity projection and 
averaged datasets calculated using the ten 3D image sets for treatment planning. 
Gross tumor volumes (GTVs) were contoured by the treating radiation oncologist using the 
individual phase (e.g., T50 (GTV_T50)) CT datasets. The IGTV was generated using either 
a union of all GTV respiratory phases or an outline of the maximum intensity CT data. The 
internal target volume (ITV) was defined as an 8 mm isotropic expansion of the IGTV, and the 
planning target volume (PTV) was defined as an expansion of the ITV by 5 mm. A clinical target 
volume (CTV) and PTV were generated from GTV with the same expansions on individual 
phases (e.g., GTV_T50, CTV_T50, and PTV_T50, respectively) for plan evaluation purposes. 
All normal structure contours were defined on time-averaged CT. A PSPT plan with two or three 
fields was generated using the methodology that we described previously(2) and reviewed by 
the treating physician for each patient. Single-field optimized (SFO) and multifield optimized 
(MFO) scanning beam proton therapy plans(11) were then generated using the Eclipse treat-
ment planning system (version 8.9; Varian Medical Systems) at the beam angles matching the 
dose distribution and DVH parameters of the PSPT plan. Specifically, an averaged 4D CT set 
with IGTV density override (i.e., assignment of maximum CT Hounsfield unit number from 
individual respiratory phases)(2) was used for all treatment plans.
B.  Dose calculation
A deformable registration technique was required to facilitate dose comparison and summation of 
different respiratory phases. To that end, an in-house software program based on an accelerated 
demons algorithm was used.(12) For each plan, the dose calculated on the averaged CT dataset 
without IGTV override was referred to as the nominal dose. Also, 3D doses were recalculated 
in each of the 10 phases of the simulation 4DCT using the same plan. The resulting ten dose 
distributions were deformed to the T50 phase for the 4D CT image set, and the 4D dose was 
calculated as the time-weighted average of these ten doses. The T50 phase was used because 
the lung at exhalation represented the most stable and repeatable phase.(13)
c.  Dose analysis
As described above, T50-phase images were used as reference image sets for planning evalua-
tion with individual phase doses and the 4D dose. DVHs were calculated using volumes defined 
on T50, noting that the DVH calculated for the predeformation dose for the predeformation 
contour (GTV_T0) should be identical to the DVH calculated for the postdeformation dose for 
the postdeformation contour (GTV_T50), provided the volume of the contour did not change. 
In other words, the DVH was invariant during dose deformation. However, the nominal dose 
was calculated on averaged CT dataset. Because the target volumes (IGTVs) differed from the 
4D dose (GTV_T50), deformation of the nominal dose and the target volume contours from 
the averaged CT to the T50 CT, or vice versa, may not have been reliable. Therefore, whereas 
voxel-based comparison of the individual phase doses and 4D dose was feasible, the same 
comparison may not be ideal for the nominal dose and 4D dose. Therefore, an area under the 
curve (AUC) DVH–based method(14,15) of quantifying the difference between different dose 
distributions was performed.
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As shown in Fig. 1, two differential DVHs were calculated using different plans or images 
for the same organ. The difference between the mean positions of two shaded regions on the 
differential DVHs (dAUC, Fig. 1(a)) represented the difference in integral/mean dose received 
by the organ, which is equivalent to the difference in AUC for cumulative DVH. Similarly, the 
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The consistency of the pre- and postdeformation DVHs could easily be validated compared 
to the validation of deformation of dose values for the individual voxels, while it also provided 
extra information on the dose deformation compared to the contour deformation.
The validity of the dAUC and eAUC in the context of the 4D dose calculations was verified 
by correlating these two parameters with the mean and standard deviation of the difference 
between the doses at individual phases and the 4D dose for different volumes. 
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Where μ is the mean dose difference between dose distribution A and B, while σ is the standard 
deviation of the dose difference. The dAUC and eAUC were then used to quantify the differ-
ence between the 3D nominal dose and the 4D dose.
 
Fig. 1. Parameterization of DVHs: (a) dAUC of two differential DVHs, (b) eAUC of two differential DVHs.
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III. rESuLtS 
Figures 2 and 3 show the dose deformation and 4D dose calculation for one of the studied 
patients. Specifically, Fig. 2(a) shows the dose distribution of the MFO plan calculated on T0 or 
the inhale phase of the 4D CT, while 2(c) shows the dose calculated on T50 or the exhale phase 
of the 4D CT. Notice the dose difference between T0 and T50 due to tumor motion indicated by 
the arrows. Figure 2(b) shows the dose calculated on T0 (Fig. 2(a)) deformed on to T50. The 
dose distribution at the same tumor location in this case is identical to Fig 2(a), as expected. Of 
note is that the patient coordinates differed (Z = 2.5 cm at T0 versus Z = 2.0 cm at T50) because 
of tumor motion. We also verified that the DVHs calculated on the predeformation doses on the 
predeformation contours were identical to the DVHs calculated on the postdeformation doses 
on the postdeformation contours.
Fig. 2. CT images showing dose deformation and 4D dose calculation for (a) one slice of a predeformed T0 dose at T0 
of the 4D CT  (Z = -2.5 cm), (b) same slice of postdeformed T0 dose at T50 of the CT (Z = -2.0 cm), and (c) same slice 
of T50 dose at T50 of the CT (Z = -2.0 cm).
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Figure 3 shows the DVHs for the GTV, CTV, and PTV and the organs at risk (OARs; lung, 
spinal cord, heart, and esophagus) for the SFO (Figs. 3(a) and (c)) and MFO (Figs. 3(b) and (d)) 
plans. The color-filled bands represent the ranges of DVHs calculated on different phases of 
the 4D CT dataset. The solid line indicates the DVH for the 4D dose calculated at T50, and the 
dashed line indicates the nominal dose calculated on the averaged CT. The difference between 
the two DVHs represents the systematic error between the 3D doses and the 4D dose.
Analyses of dAUC, eAUC, and voxel-based evaluation of the PTV for different patients 
between T50 and 4D doses are shown in Fig. 4(a). The red circles and cyan crosses represent 
the mean and standard deviation of the mean DT50-D4D, respectively, for voxels in the PTV for 
different patients, and the blue and green lines represent the dAUC(DT50, D4D) and eAUC(DT50, 
D4D), respectively. Fig. 4(b) shows the Pearson correlation coefficients for the dAUC(D3D, D4D) 
and μ(D3D-D4D) of the GTV, CTV, and PTV at different phases (solid lines) and for the lung, 
spinal cord, esophagus, and heart (dashed lines; p < 0.05 in all cases). Figure 4(c) shows the linear 
fit with all MFO data points (all patients, structures, and phases) between dAUC(D3D, D4D) and 
μ(D3D-D4D); the overall correlation coefficient was 0.996 (p < 0.01). Similarly, Fig. 4(d) shows 
the Pearson correlation coefficients between eAUC(D3D, D4D) and σ(D3D-D4D), and Fig. 4(e) 
shows the linear fit with all MFO data points, with an overall correlation coefficient of 0.723 
(p < 0.05). These results indicated that dAUC and eAUC are good metrics for quantification 
of the differences among dose distributions.
Figures 5(a) and 5(c) show the dAUC(Dnominal-D4D) and eAUC(Dnominal-D4D) for the GTV, 
CTV, and PTV with the SFO and MFO plans, respectively, and Figs. 5(b) and 5(d) show these 
two quantities as functions of tumor motion. The dAUC between the nominal and 4D doses, 
which represents the mean dose error from the 3D dose calculation, was less than 1.5% in the 
GTV and CTV for all patients, but was greater than 2% in the PTV for one patient. Similarly, 
Fig. 3. DVHs of the nominal and 4D doses in a lung cancer patient: (a) DVHs for the GTV and CTV for the SFO plan; 
(b) DVHs for the GTV and CTV for the MFO plan; (c) DVHs for the PTV and OARs (lung, spinal cord, heart, and 
esophagus) for the SFO plan; (d) DVHs for the PTV and OARs for the MFO plan.
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the eAUC, which represents the standard deviation of the mean dose error, was less than 2% for 
all but one patient. The maximum point dose error was greater than 6% in the GTV and greater 
than 10% in the CTV and PTV. We found no significant differences between the dose error with 
the MFO and SFO plans for the GTV, CTV, and PTV according to Student’s t-test results.
Fig. 4. Correlation between the DVH and voxel-based metrics for all patients: (a) plot of the dAUC, dAUC, and mean 
and standard deviation of the dose difference for all voxels in the PTV between DT50 and D4D in the ten study patients; 
(b) correlation between the dAUC and mean dose difference at different respiratory phases; (c) linear fit of the dAUC and 
mean dose difference for all patients, structures, and phases; (d) correlation between the eAUC and standard deviation 
of the mean dose difference at different respiratory phases; (e) linear fit of the eAUC and standard deviation of the dose 
difference for all patients, structures, and phases.
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For comparison purpose, we also repeated the calculation for the PSPT plans. Similar results 
were found where dAUC between the nominal and 4D doses was less than 1% in the GTV 
for all patients, and less than 2% for all patients in the CTV and PTV. There were statistical 
significant difference between PSPT and SFO (MFO) for dAUC of GTV (p < 0.05), but no 
significant differences were found for other quantities with Student’s t-test.
 
IV. DIScuSSIon
In this study, we applied AVE_RIGTV planning, which was developed for PSPT, to scanning 
beam proton therapy. Our purpose was to evaluate the systematic dose error resulting from using 
the nominal 3D dose instead of the 4D accumulated doses for lung cancer patients. Our results 
demonstrated that the systematic dose error was highly patient-specific, but not dependent on 
the planning technique (SFO or MFO). The maximum point dose errors were greater than 6% 
for the GTV and greater than 10% for the CTV and PTV. However, the mean and standard 
deviation of the dose error for the GTV, CTV, and PTV was less than 1.5% for all but one 
patient. Although GTV coverage was maintained on all phases with IGTV override, CTV and 
PTV coverage could be degraded in some phases, as shown in Fig. 2. The magnitude of tumor 
motion was not a predictor of dose uncertainty, as the proton dose distribution was affected not 
only by tumor motion but also by tissue-density change in the beam path. Overall, we found 
the AVE_RIGTV planning technique to be effective for scanning beam proton therapy planning 
of lung cancer before 4D planning and dose calculation become readily available. A point of 
Fig. 5. Patient-specific evaluation of the impact of tumor motion on dose: (a) the dAUC between the nominal and 4D doses 
in the ten studied patients for the SFO and MFO plans; (b) the dAUC between the nominal and 4D doses as a function of 
tumor motion; (c) the eAUC between the nominal and 4D doses in the ten studied patients for the SFO and MFO plans; 
(d) the eAUC between the nominal and 4D doses as a function of tumor motion.
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emphasis is that patient-specific evaluation is important and 4D dose calculations are recom-
mended, whereas evaluation of the T0 and T50 dose should be kept as a minimum.
Previous study showed that smearing margin for setup uncertainty also played a role in tak-
ing account of target motion.(2) While there was no smearing margin in scanning beam proton 
therapy, the lateral falloff of the spot, or the spot size, effectively serve as smearing margin. 
For our system with relative large spot size, our results showed that there were no statistical 
difference between scanning and passive scattering proton therapy for CTV and PTV. More 
in-depth investigation will be necessary to fully understand the effect of spot size and spacing. 
The relationship between robustness and motion uncertainty, along with the investigation of 
optimal planning margins, will be presented in a different study.
DVHs are invariant for dose deformation given that the organ volume does not change. 
Therefore, dAUC and eAUC are good metrics for quantifying the variations among different 
doses on different patient images. Our results demonstrated that dAUC is a good predictor of 
the mean dose error, and that eAUC is a good predictor of the standard deviation of the dose 
error between 3D and 4D doses for all structures and patients. These predictors may be useful 
not only for 4D dose calculation, but also for adaptive planning throughout the treatment.
 
V. concLuSIonS
In this study, we evaluated the systematic dose error resulting from 3D dose calculation for 
scanning beam proton therapy. The dose error in 3D dose calculation varies from patient to 
patient and does not correlate with lung tumor motion. Therefore, patient-specific evaluation of 
the 4D dose is important for scanning beam proton therapy for lung tumors. Before 4D planning 
and dose calculation become readily available, AVE_RIGTV planning technique is effective 
for scanning beam proton therapy planning of lung cancer.
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